are also associated with a greater risk of NAFLD and NASH at any given body mass index, and preliminary evidence suggests greater liver fat content in certain ethnicities that are also known to be at increased risk of type 2 diabetes. Preliminary evidence suggests a genetic predisposition to hepatic accumulation of fat in some people through the PNP3A gene. Such people may not necessarily displ...

Nonalcoholic fatty liver disease (NAFLD) is present in up to one third of the general population and in the majority of patients with metabolic risk factors such as obesity and diabetes. Insulin resistance is a key pathogenic factor resulting in hepatic fat accumulation. Recent evidence demonstrates NAFLD in turn, exacerbates hepatic insulin resistance and often precedes glucose intolerance. On...

The high prevalence of non-alcoholic fatty liver disease (NAFLD) has made the condition an important public health issue. Two clinical entities are manifestations of NAFLD, namely, non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). The former tends to be benign and non-progressive while the latter can progress to cirrhosis, which in rare cases gives rise to hepatocellula...

Published articles have been reprinted with the permission of the copyright holder. Till Charlotte och Moa! Of all knowledge, there is nothing greater than to know that You love me. Abstract Fatty liver has previously often been associated with excessive alcohol consumption. During the last two decades, the interest in fatty liver occurring in non-drinkers i.e. non-alcoholic fatty liver disease...

Obesity and metabolic syndrome are healthcare problems that continue to rise in frequency worldwide. Both phenotypes are a strong predictor for development of liver steatosis in the context of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis. Ultrasound may detect steatosis, but its sensitivity is limited and liver biopsy is still considered to be the gold standard. Less invas...

Background: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease which is correlated with overweight, obesity, and insulin resistance. Recently, the use of probiotics has been suggested for these patients as they have considerable outcomes. The aim of the present study is to evaluate the effect of GeriLact on patients with NAFLD. Method:</...

BACKGROUND There are insufficient data available on utilization and health care costs of non-alcoholic fatty liver disease. The cost data for different health conditions and services is a major gap in Iranian health system. So this study is the primary or first step towards filling this gap. OBJECTIVES This study aims to estimate the diagnosis and treatment costs of Non-alcoholic Fatty Liver....